Search Results

January 2022 "Watch our CEO Tim Dyer on AlphaStreet. In his interview, Mr. Dyer provides an overview of our #allostericmodulator pipeline and the potential $4 billion market for our lead compound #dipraglurant in #PDLID (#Parkinsonsdisease levodopa-induced #dyskinesia)." Read more at the source #DrGPCR #GPCR #IndustryNews

Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumour in adults. Treatments include surgical resection, radiotherapy, and chemotherapy. Despite this, the prognosis remains poor, with an impacted quality of life during treatment coupled with brain tumour recurrence; thus, new treatments are desperately needed. In this review, we focus on recent advances in G-protein-coupled receptor (GPCR) targets. To date, the most promising targets are the chemokine, cannabinoid, and dopamine receptors, but future work should further examine the melanocortin receptor-4 (MC4R), adhesion, lysophosphatidic acid (LPA) and smoothened (Smo) receptors to initiate new drug-screening strategies and targeted delivery of safe and effective GBM therapies. Read full article

GPCR Symposium on 'GPCRs as Therapeutic Modalities'. Want to share your project in a casual way? npr-38 regulates avoidance and stress-induced sleep in Caenorhabditis elegans Towards the convergent therapeutic Results, Provides Corporate Updates, and Reports Emerging Data from Chronic Neutropenia Clinical Program Structure Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights GPCR Events, Meetings MPGPCR Conference (November 15 -17, 2023) ASCEPT Annual Scientific Meeting (November 20 -23, 2023) Structure

September 2022 "Background G protein-coupled receptor (GPCR) is the most targeted protein family by the FDA-approved drugs. GPCR-kinase 3 (GRK3) is critical for GPCR signaling. Our genomic analysis showed that GRK3 expression correlated with poor prognosis of gastric adenocarcinoma (GAC) patients. However, GRK3’s functions and clinical utility in GAC progression and metastases are unknown. Methods We studied GRK3 expression in normal, primary, and metastatic GAC tissues. We identified a novel GRK3 inhibitor, LD2, through a chemical-library screen. Through genetic and pharmacologic modulations of GRK3, a series of functional and molecular studies were performed in vitro and in vivo. Impact of GRK3 on YAP1 and its targets was determined." Read more at the source #DrGPCR #GPCR #IndustryNews

April 2022 Addex Therapeutics Completes Patient Enrollment For Dipraglurant Blepharospasm Phase 2 Clinical Study "Geneva, Switzerland, April 13, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage

VIB spin-off Confo Therapeutics today announced that it has entered into a collaborative agreement with in disease-relevant conformations, will be applied with the goal of enabling the discovery of novel therapeutic

July 2022 Confo Therapeutics receives €1.7 million VLAIO grant for further research on GPCR modulators for rare diseases "29/06/2022 Confo Therapeutics, founded in 2015 as a spin-off from VIB and VUB, announced The grant should help expand Confo Therapeutic’s research on G protein-coupled receptor (GPCR) drug candidates

Therapeutic antagonism of the neurokinin 1 receptor in endosomes provides sustained pain relief. Structural and Molecular Insights into GPCR Function Cholesterol Biases the Conformational Landscape Structural genomics of the human dopamine receptor system Structural Insights into Molecular Recognition Decline in Patients with Idiopathic Pulmonary Fibrosis Exscientia Business Update for First Quarter 2023 Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for the Treatment of Type 2 Diabetes

Our next symposium is on July 21st, 2023, focusing on Structural and Molecular Insights into GPCR Activation Andrew Hopkins, Exscientia’s founder and CEO was elected a Fellow of the Academy of Medical Sciences Structure Therapeutics Announces Poster Presentations at the American Thoracic Society International Conference

Dr Brennan has extensive experience across all phases of clinical development, and across multiple therapeutic

Methods & Updates in GPCR Research Mapping of structural arrangement of cells and collective calcium Structural and Molecular Insights into GPCR Function The role of G protein conformation in receptor-G Industry News Addex Provides Corporate Update And Financial Guidance Structure Therapeutics Appoints Industry Leaders Eric Dobmeier and Joanne Waldstreicher to its Board of Directors GPCR Therapeutics launches

August 2022 Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia "BOSTON--(BUSINESS WIRE)--Aug. 8, 2022-- Karuna Therapeutics, Inc.

March 2022 "Geneva, Switzerland, March 7, 2022 – Addex Therapeutics (SIX: ADXN, Nasdaq: ADXN), a clinical-stage

Structural and Molecular Insights into GPCR Function New Insights into the Structure and Function of 2 Epilepsy Clinical Study’s Independent Interim Review Committee Recommends Continuing Study Addex Therapeutics Therapeutics Reports First Quarter 2023 Financial Results and Recent Highlights OMass Therapeutics presented BioEquity Conference British Patient Capital Invests £10m in next-generation drug development company OMass Therapeutics GPCR Events, Meetings, and Webinars ASPET 2023 - American Society for Pharmacology and Experimental Therapeutics

tunes mGlu5 receptor function, impacting synaptic transmission Orphan receptor GPR88 as a potential therapeutic effect as agonist's efficacy Single transmembrane GPCR modulating proteins: neither single nor simple Structural and Molecular Insights into GPCR Function Insights on the G protein-coupled receptor helix 8 solution structure , functional, and therapeutic perspective Structural basis for selectivity and antagonism in extracellular GPCR-nanobodies Industry News Structure Therapeutics Reports Positive Topline Data from its Phase 2a

Industry News Biotech startup Structure pulls off rare IPO, raising $161M 3-drug combo leads to 'unprecedented ' response in pancreatic cancer models Addex Therapeutics Ltd Strategic Partner Completes Enrollment in ADX71149 Epilepsy Phase 2 Study Part 1 IPO Raises $161M for GPCR-Based Drug Developer Structure Therapeutics Business Development & Strategy CADD and Informatics Head or Team Lead (depending on experience) with Structural

December 2021 OMass Therapeutics's founder, Carol Robinson, has been awarded the prestigious Louis-Jeantet

March 2022 Confo Therapeutics Doses First Subjects In Phase 1 Clinical Trial Of CFTX-1554 For The Treatment Confo’s first drug candidate moves into clinical development — Ghent, Belgium – March 10, 2022 – Confo Therapeutics

We’re glad to have Peter's dedication, experience, and passion in building innovative therapeutics."

October 2022 "We describe production of the human A2A adenosine receptor (A2AAR), a class A G protein-coupled receptor (GPCR) for 19F-NMR and single-molecule fluorescence (SMF) spectroscopy. We explain in detail steps shared between the two sample preparation strategies, including expression and isolation of A2AAR and assembly of A2AAR in lipid nanodiscs and procedures for incorporation of either 19F-NMR or fluorescence probes. Protocols for SMF experiments include sample setup, data acquisition, data processing, and error analysis. For complete details on the use and execution of this protocol, please refer to Wei et al. (2022) and Sušac et al. (2018)." Read more at the source #DrGPCR #GPCR #IndustryNews

August 2022 "Geneva, Switzerland, August 18, 2022 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage

Kogut-Günthel , Antonella Di Pizio , et al. for their research on The path to the G protein-coupled receptor structural Discovery on Target’s 19th Annual GPCR-Based Drug Discovery Targeting G Protein-Coupled Receptors for New Therapeutic Modalities A quick revision of how β-adrenergic receptors work and how their antagonists can achieve therapeutic Therapeutics Appoints Angus C. GPCRs, and more G Protein-Coupled Receptors in Skin Aging The path to the G protein-coupled receptor structural

mechanism of traditional Chinese medicine in the treatment of glioblastoma multiforme Industry News Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist Half-Year Financial Results and Exciting Developments at Aelis Farma Ion Channel Drug Developer Maxion Therapeutics Lefkowitz's Career at Duke October 3, 2023, | FREE Seminar: Changing paradigm on Therapeutics targeting

November 2021 "Nov. 15, 2021 LONDON – There’s not yet proof of the pudding, but Omass Therapeutics Ltd .’s new structure-based technology has passed a key test, in enabling the discovery of orally available

, GPCRs, and more RGS proteins and cardiovascular Angiotensin II Signaling: Novel opportunities for therapeutic Study of G protein-coupled receptors dimerization: From bivalent ligands to drug-like small molecules Structural for Daridorexant (ACT-541468), a Dual Orexin Receptor Antagonist for the Treatment of Insomnia OMass Therapeutics Releases First Protein Structures in PDB, Advances Lupus Therapy Research Structure Therapeutics Receives

Therapeutic potential of opioid receptor heteromers in chronic pain and associated comorbidities. Structural and Molecular Insights into GPCR Function Predicted Three-Dimensional Structure of the GCR1 Structural insights into constitutive activity of 5-HT6 receptor. Industry News Confo Therapeutics Enters into Collaboration Agreement with Daiichi Sankyo to Discover Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Highlights Salipro

Odorant G protein-coupled receptors as potential therapeutic targets for adult diffuse gliomas: a systematic Glioma is the most common adult malignant brain tumor and requires novel therapeutic strategies to improve genomic and transcriptomic profiles of ORs in glioma, we suggest that ORs are potential biomarkers and therapeutic

October 2022 Mechanism of enhanced sensitivity of mutated β-adrenergic-like octopamine receptor to amitraz in honeybee Apis mellifera: An insight from MD simulations "Background: Amitraz is one of the critical acaricides/insecticides for effective control of pest infestation of Varroa destructor mite, a devastating parasite of Apis mellifera, because of its low toxicity to honeybees. Previous assays verified that a typical G protein-coupled receptor, β-adrenergic-like octopamine receptor (Octβ2R), is the unique target of amitraz, but the honeybee Octβ2R resists to amitraz. However, the underlying molecular mechanism of the enhanced sensitivity or toxicity of amitraz to mutated honeybee Octβ2RE208V/I335T/I350V is not fully understood. Here, molecular dynamics simulations are employed to explore the implied mechanism of the enhanced sensitivity to amitraz in mutant honeybee Octβ2R." Read more at the source #DrGPCR #GPCR #IndustryNews